# FS-X2

Source: https://onco.cc/drugs/fs-x2/  
OnCo record `fs-x2` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

FS-X2 is an experimental small molecule from Fushi Biotechnology, in preclinical development for CCNE1-positive solid tumours.

## Summary

FS-X2 is a small molecule (company platform is fragment-based small-molecule discovery) from Fushi Biotechnology. Targets PKMYT1; the company lists it for CCNE1-positive solid tumours (written 'CCEN1+' on the site). Its furthest stage is preclinical development, for CCNE1-positive solid tumours. No clinical trial naming it is registered on ClinicalTrials.gov. Pipeline milestone: IND 2027 Q2. It has not been shown to work in people.

## Fields

- Kind: Treatment
- Status: preclinical
- Last checked: 2026-11-03
- Tags: pipeline
- Code: FS-X2
- Modality: Small molecule (company platform is fragment-based small-molecule discovery)
- Mechanism: Targets PKMYT1; the company lists it for CCNE1-positive solid tumours (written 'CCEN1+' on the site).

## Sources

- Fushi Biotechnology: foresightbiopharm.com: https://www.foresightbiopharm.com/en/pipeline.html

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)
- companies: [Fushi Biotechnology](https://onco.cc/companies/fushi-biotechnology/)

---
JSON: https://onco.cc/api/v1/entities/fs-x2.json